AgeX Therapeutics to Present at Undoing Aging 2019, March 28-30 in Berlin, Germany
March 21 2019 - 7:00AM
Business Wire
AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology
company focused on innovative therapeutics for human aging,
announced today that the company will present in multiple sessions
at Undoing Aging 2019, March 28-30 in Berlin, Germany.
Details of the company’s participation follow:
- Thursday, March 28, 7:00pm CET:
“Debate: is comprehensive damage repair feasible?” with
Aubrey de Grey, Ph.D., AgeX’s VP, New Technology Discovery and
Vadim Gladyshev, Ph.D., Professor of Medicine at Harvard Medical
School.
- Friday, March 29, 10:00am CET: As part
of the track “Restoring Cellular Youth,” AgeX’s Founder and
CEO Michael D. West, Ph.D., will deliver an update on the Company’s
regenerative medicine product development, and in addition, present
for the first time data relating to central molecular aging
clockwork mechanisms the Company is targeting with its induced
Tissue Regeneration (iTRTM) program.
The conference also features a track, “Senolysis,” inspired in
part by Dr. West’s research:
“It has been two decades since West and
Campisi began to suggest that senescent cells might be more than
just disabled, but actively toxic. Since 2011, their idea has not
only been confirmed in the lab but has spawned a huge range of
ideas for eliminating such cells, many of which are already being
pursued in startups. The rate of progress is such that a single
session at UA can no longer do justice to it - so, we're having
two!”
A copy of Dr. West’s presentation will be made available on the
AgeX website.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on
developing and commercializing innovative therapeutics for human
aging. Its PureStem® and UniverCyte™ manufacturing and
immunotolerance technologies are designed to work together to
generate highly defined, universal, allogeneic, off-the-shelf
pluripotent stem cell-derived young cells of any type for
application in a whole host of diseases with a high unmet medical
need. AgeX has two preclinical cell therapy programs: AGEX-VASC1
(vascular progenitor cells) for tissue ischemia and AGEX-BAT1
(brown fat cells) for Type II diabetes. AgeX’s revolutionary
longevity platform named induced Tissue Regeneration (iTR™) aims to
unlock cellular immortality and regenerative capacity to reverse
age-related changes within tissues. AGEX-iTR1547 is an iTR-based
formulation in preclinical development. HyStem® is AgeX’s
delivery technology to stably engraft PureStem cell therapies and
slowly release iTR molecules in the body. AgeX is developing its
core product pipeline for use in the clinic to extend human
healthspan, and is seeking opportunities to form licensing and
partnership agreements around its broad IP estate and proprietary
technology platforms for non-core clinical applications.
For more information, please visit www.agexinc.com or connect
with the company on Twitter, Facebook and YouTube.
Forward-Looking Statements
Certain statements contained in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are
not historical fact including, but not limited to statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates” should also be considered forward-looking
statements. Forward-looking statements involve risks and
uncertainties. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that
affect the business of AgeX Therapeutics, Inc. and its
subsidiaries, particularly those mentioned in the cautionary
statements found in more detail in the “Risk Factors” section of
AgeX’s Information Statement filed as an exhibit to its
Registration Statement on Form 10 with the Securities and Exchange
Commissions (copies of which may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. AgeX specifically disclaims any obligation or
intention to update or revise these forward-looking statements as a
result of changed events or circumstances that occur after the date
of this release, except as required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190321005290/en/
Media Contact for AgeX:
Bill DouglassGotham Communications, LLCbill@gothamcomm.com(646)
504-0890
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Apr 2023 to Apr 2024